Research programme: macrocyclic compounds - Bristol-Myers Squibb/Oncodesign

Drug Profile

Research programme: macrocyclic compounds - Bristol-Myers Squibb/Oncodesign

Latest Information Update: 13 Jan 2016

Price : $50

At a glance

  • Originator Oncodesign Biotechnology
  • Class Antineoplastics; Macrocyclic compounds; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer; Unspecified

Most Recent Events

  • 05 Jan 2016 Early research in Undefined indication in France (unspecified route)
  • 05 Jan 2016 Early research in Cancer in France (unspecified route)
  • 05 Jan 2016 Oncodesign and Bristol-Myers Squibb agree to co-develop macrocyclic compounds for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top